Takeaways: By combining a TSXV listing with a Health Canada-accepted ANDS for a domestically made generic Ozempic, Vimy is positioning itself to compete in a fast-growing, high-value GLP-1 marke...
Takeaways: Vimy Pharma’s filing could position it as a domestic, lower-cost semaglutide supplier in Canada, which supports affordability and national supply resilience. The broader market ...
